• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women with ADHD have to make a difficult choice on whether to keep or stop taking ADHD medication during pregnancy and breastfeeding. There are few data on how long-term exposure may affect the fetus.

A recent study published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological problems like hearing loss or vision, febrile seizures or IQ impairment. The authors acknowledge the need for higher-quality research.

Risk/Benefit Analysis

Women who are pregnant and taking ADHD medications must weigh the benefits of taking them against the potential risks to the fetus. Doctors don't have the data needed to provide clear recommendations however they can provide information on the risks and benefits to help pregnant women make informed decisions.

A study published in Molecular Psychiatry found that women who took ADHD medications in early pregnancy did not face an increased risk of fetal cardiac malformations or major structural birth defects. Researchers conducted a large population-based case control study to assess the frequency of structural defects that were major in infants born to mothers who took stimulants during pregnancy. Pediatric cardiologists, clinical geneticists and other experts looked over the cases to make sure that the classification was accurate and to minimize any bias.

The study of the researchers was not without its limitations. The researchers were unable in the beginning to distinguish the effects of the medication from the disorder. This makes it difficult to know whether the limited associations observed in the groups that were exposed result from medication use or comorbidities that cause confusion. The researchers also did not look at the long-term effects for the offspring.

The study revealed that infants whose mother had taken ADHD medication during pregnancy had a higher chance of being admitted to the neonatal care unit (NICU) as compared to mothers who did not take any medication during pregnancy or quit taking the medication prior to or during pregnancy. The reason for this was central nervous system disorders. The higher risk of admission was not affected by the stimulant medication used during pregnancy.

Women who were taking stimulant ADHD medications during pregnancy also had a higher likelihood of having an emergency caesarean section or having one whose baby scored low on the Apgar scale (less than 7). These increases appear to be independent of the type of medication used during pregnancy.

The research suggests that the small risk associated with the use of ADHD medications during the early stages of pregnancy may be offset by the higher benefit for both mother and child of continued treatment for the woman's disorder. Physicians should discuss the issue with their patients and, if possible, help them develop strategies to improve coping skills which can reduce the effects of her disorder on her daily functioning and relationships.

Interactions with Medication

More and more doctors are confronted with the dilemma of whether to keep treatment or stop it during pregnancy as more women are diagnosed with ADHD. Most of the time, these decisions are taken in the absence of solid and reliable evidence either way, so physicians must weigh what they know about their experiences, the experiences of other doctors, and what the research says on the topic as well as their best judgment for each individual patient.

The issue of potential risks for infants can be extremely difficult. A lot of studies on this subject are based on observations rather than controlled research, and their conclusions are often contradictory. The majority of studies focus on live-births, which could underestimate the teratogenic impact leading to terminations or abortions of pregnancy. The study discussed in the journal club addresses these limitations by analyzing information on deceased and live births.

Conclusion A few studies have found a positive correlation between ADHD medications and certain birth defects However, other studies haven't found a correlation. The majority of studies show that there is a neutral, or slight negative impact. As a result, a careful risk/benefit assessment is required in every case.

For many women with ADHD who suffer from ADHD, the decision to stop medication can be difficult, if not impossible. In a recent piece published in the Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can a general practitioner prescribe adhd medication increase depression and feelings of being isolated. A loss of medication may affect the ability to safely drive and perform work-related tasks, which are vital aspects of everyday life for those suffering from adhd medication how does it work.

She suggests women who are uncertain about whether to continue or discontinue medication due to their pregnancy, consider informing family members, friends and colleagues on the condition, its impact on daily life, and the advantages of staying on the current treatment regimen. It can also help a woman feel supported in her decision. Certain medications can pass through the placenta. If a patient decides not to take her ADHD medication while breastfeeding, it is crucial to be aware that the medication could be passed on to her infant.

Birth Defects Risk

As the use and misuse of ADHD medication to treat symptoms of attention deficit hyperactivity disorder (ADHD) is increasing the concern over the potential adverse effects of the drugs on foetuses. A study that was published in the journal Molecular Psychiatry adds to the existing knowledge on this subject. Utilizing two huge data sets, researchers were able to examine more than 4.3 million pregnancies and see whether stimulant medications increased the risk of birth defects. Although the risk overall remains low, the scientists found that exposure in the first trimester to ADHD medications was linked to a slightly higher rate of certain heart defects, such as ventriculoseptal defect (VSD).

The researchers of the study didn't discover any connection between early medication usage and other congenital anomalies, like facial deformities or club feet. The results are in the same vein as previous studies which showed the existence of a slight, but significant increase in cardiac malformations for women who began taking ADHD medication before the birth of their child. The risk grew in the latter half of pregnancy, when a lot of women begin to discontinue their ADHD medication.

Women who took ADHD medications in the first trimester of pregnancy were also more likely to experience a caesarean section, a low Apgar score after delivery and a baby that required help breathing at birth. However, the authors of the study were not able to eliminate bias due to selection by limiting the study to women who didn't have any other medical issues that could have contributed to these findings.

The researchers hope their research will help inform the clinical decisions of physicians who encounter pregnant women. They suggest that although discussing risks and benefits is important but the decision to stop or keep treatment must be based on each woman's needs and the severity of her ADHD symptoms.

The authors caution that, even though stopping the medication is a possibility to consider, it is not recommended because of the high incidence of depression and other mental problems among women who are pregnant or who have recently given birth. Additionally, the research suggests that women who choose to stop taking their medication are more likely to have a difficult time getting used to life without them after the birth of their baby.

Nursing

It can be overwhelming becoming a mother. Women with generic adhd medications who have to deal with their symptoms while attending physician appointments, preparing for the arrival of a baby and adapting to new routines in the home may face a lot of challenges. Therefore, many women elect to continue taking their ADHD medications throughout pregnancy.

The risk to a breastfeeding infant is minimal because the majority of stimulant medications is absorbed through breast milk at a low level. However, the amount of exposure to medications by the infant can differ based on dosage, frequency it is taken and the time of day the medication for odd and adhd (simply click the next document) is administered. In addition, individual medications enter the baby's system differently through the gastrointestinal tract as well as breast milk. The impact of this on a newborn infant is not yet fully understood.

Some doctors may stop taking stimulant medication during a woman's pregnancy due to the lack of research. This is a difficult decision for the patient, who must balance the benefit of continuing her medication against the possible risks to the embryo. As long as there is no more information, doctors should ask all pregnant patients about their experience with ADHD and whether they plan or are taking to take medication during the perinatal time.

A increasing number of studies have proven that most women can safely continue taking their ADHD medication while they are pregnant and nursing. As a result, an increasing number of patients choose to do so and in consultation with their doctor they have discovered that the benefits of continuing their current medication exceed any risk.

It is crucial for women suffering from ADHD who are thinking of breastfeeding to seek a specialist psychiatrist's advice prior to becoming pregnant. They should discuss their medication with their prescriber, and the pros and cons of continuing treatment. This includes non-pharmacological strategies. Psychoeducation is also required to help pregnant women suffering from ADHD be aware of the symptoms and underlying disorder. They should also be educated about treatment options and strengthen strategies for coping. This should be a multidisciplinary approach with the GP, obstetricians and psychiatry. Pregnancy counselling should include discussion of a management plan for both the mother and child, monitoring for signs of deterioration and when necessary, making adjustments to the medication regimen.